Yu Zhenghang, Liang Dianyuan, Zhang Zhongyang, Song Ke, Zhang Yuan, Xian Yin, He Ming, Xie Xing, Xie Sijun, Kong Xiangxin, Ren Yixing
Institute of Hepatobiliary Pancreatic Intestinal Diseases, North Sichuan Medical College, Nanchong, 637000, China.
Department of Gastroenterology, Affiliated Hospital of North Sichuan Medical College, Nanchong, 637000, China.
Obes Surg. 2025 Apr;35(4):1297-1306. doi: 10.1007/s11695-025-07742-7. Epub 2025 Mar 14.
Obesity is a predisposing factor for the onset of hypertriglyceridemia-induced acute pancreatitis (HTG-AP). Metabolic and bariatric surgery (MBS) has demonstrated significant short-term efficacy in the treatment of HTG-AP. The current evaluated the long-term efficacy of MBS for the management of recurrent HTG-AP.
Between 01 January 2015 and 31 August 2019, a total of 51 patients diagnosed with obesity combined with HTG-AP at our hospital were enrolled in the study. 14 underwent laparoscopic sleeve gastrectomy (LSG), 9 underwent laparoscopic Roux-en-Y gastric bypass (LRYGB), and 28 underwent routine treatment including dietary therapy, pharmacotherapy, and plasma exchange. The aim of the study was to investigate the long-term therapeutic effects of LRYGB, LSG, and routine treatment on recurrent HTG-AP, and to assess patient prognoses under different treatment modalities.
The LSG and LRYGB groups achieved significant average weight loss, whereas the changes in the routine treatment group were not significant. The LRYGB group exhibited more weight loss than the LSG group. In both the LSG and LRYGB groups triglyceride levels decreased significantly within the first year after surgery. The routine treatment group exhibited a pancreatitis recurrence rate of 57.14%, compared to 15.38% in the LSG group and 11.11% in the LRYGB group.
Over a period of 5 years, LSG and LRYGB exhibited superior efficacy with respect to managing metabolic syndrome associated with recurrent HTG-AP, particularly by enhancing weight management and reducing the pancreatitis recurrence rate. These findings support the long-term efficacy of MBS for the treatment of recurrent HTG-AP.
肥胖是高甘油三酯血症性急性胰腺炎(HTG-AP)发病的一个诱发因素。代谢和减重手术(MBS)已在HTG-AP的治疗中显示出显著的短期疗效。本研究评估了MBS治疗复发性HTG-AP的长期疗效。
2015年1月1日至2019年8月31日,共有51例在我院被诊断为肥胖合并HTG-AP的患者纳入本研究。14例行腹腔镜袖状胃切除术(LSG),9例行腹腔镜Roux-en-Y胃旁路术(LRYGB),28例行包括饮食治疗、药物治疗和血浆置换在内的常规治疗。本研究的目的是探讨LRYGB、LSG和常规治疗对复发性HTG-AP的长期治疗效果,并评估不同治疗方式下患者的预后。
LSG组和LRYGB组平均体重显著减轻,而常规治疗组体重变化不显著。LRYGB组比LSG组减重更多。LSG组和LRYGB组术后第一年甘油三酯水平均显著下降。常规治疗组胰腺炎复发率为57.14%,而LSG组为15.38%,LRYGB组为11.11%。
在5年的时间里,LSG和LRYGB在管理与复发性HTG-AP相关的代谢综合征方面表现出卓越的疗效,特别是在加强体重管理和降低胰腺炎复发率方面。这些发现支持MBS治疗复发性HTG-AP的长期疗效。